FDA has rejected Summit Therapeutics’ lung cancer drug ivonescimab, a PD-1/VEGF combination developed with Akeso, for a narrow setting, according to a STAT+ report. In an FDA letter, regulators said the antibody showed disease-control activity but did not improve overall survival, which the agency said failed to support a favorable benefit-risk profile for approval. For Summit, the decision is a regulatory setback for a late-stage asset being developed outside China, even as ivonescimab’s class relevance keeps commercial momentum focused on PD-1/VEGF strategies. The rejection also underscores the heightened scrutiny on survival endpoints in oncology approvals, particularly for immunotherapy combinations.